Current status of pyrazoloacridine as an anticancer agent
Author:
- 1 February 1999
- journal article
- review article
- Published by Springer Nature in Investigational New Drugs
- Vol. 17 (1) , 43-48
Abstract
Pyrazoloacridine (PZA) is the first of a new class of rationally synthesized acridine derivatives to undergo clinical testing as an anticancer agent. Recent studies suggest that PZA might be a dual...Keywords
This publication has 17 references indexed in Scilit:
- Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.1998
- Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinomaInvestigational New Drugs, 1998
- Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.Journal of Clinical Oncology, 1998
- Pyrazoloacridine for the Treatment of Hormone-Refractory Prostate CancerCancer Investigation, 1998
- Clinical trials referral resource. Clinical trials with pyrazoloacridine.1997
- Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.1997
- Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cellsBiochemical Pharmacology, 1996
- Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell lineCancer Chemotherapy and Pharmacology, 1990
- The Pyrazoloacridines: Approaches to the Development of a Carcinoma-Selective Cytotoxic AgentCancer Investigation, 1990
- The problem of the quiescent cancer cellAdvances in Enzyme Regulation, 1989